Handelsbanken Fonder’s Akero Therapeutics AKRO Stock Holding History

Handelsbanken Fonder’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,000	Closed	-$997K	–	1501
2025 Q3	$997K	Hold	21,000	–	–	﹤0.01%	1004
2025 Q2	$1.12M	Hold	21,000	–	–	﹤0.01%	912
2025 Q1	$850K	Hold	21,000	–	–	﹤0.01%	1003
2024 Q4	$584K	Buy	21,000 +1,000	+5%	+$30.3K	﹤0.01%	1228
2024 Q3	$574K	Buy	20,000 +2,200	+12%	+$57.4K	﹤0.01%	1192
2024 Q2	$418K	Buy	17,800 +8,000	+82%	+$171K	﹤0.01%	1231
2024 Q1	$248K	Hold	9,800	–	–	﹤0.01%	1443
2023 Q4	$229K	Buy	9,800 +300	+3%	+$5.92K	﹤0.01%	1482
2023 Q3	$481K	Hold	9,500	–	–	﹤0.01%	1072
2023 Q2	$444K	Buy	9,500 +2,600	+38%	+$119K	﹤0.01%	1135
2023 Q1	$264K	Hold	6,900	–	–	﹤0.01%	1345
2022 Q4	$378K	Buy	+6,900	New	+$296K	﹤0.01%	1115

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Handelsbanken Fonder's AKRO Position: Q4 2025 in Review

Handelsbanken Fonder sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 21,000 shares — an estimated $997K sold.

Handelsbanken Fonder first reported a position in AKRO in Q4 2022 and held it in 12 quarters. The position peaked at $1.12M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Handelsbanken Fonder reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Handelsbanken Fonder sold 21,000 Akero Therapeutics shares in Q4 2025, an estimated $997K.
Handelsbanken Fonder first reported a position in Akero Therapeutics in Q4 2022 and held it in 12 quarters.
Handelsbanken Fonder's Akero Therapeutics position peaked at $1.12M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Handelsbanken Fonder's 13F filing for Q4 2025, filed 6 Feb 2026.